Merck: New Real-World MAVENCLAD Data Show Sustained Effectiv

New data presented at ECTRIMS 2021 highlight improvement in measures of physical and mental health of patients with relapsing multiple sclerosis (RMS) after one year of treatment with MAVENCLAD

Related Keywords

Norway , United States , Australia , Iceland , Liechtenstein , Canada , , Merck Press , European Commission , Global Head Of Development For The Healthcare , European Union , Serono , Research In Multiple Sclerosis , European Committee For Treatment , European Committee , Multiple Sclerosis , Danny Bar Zohar , Global Head , Cladribine Tablets Treating , Oral Cladribine , Oral Cladribine Added , Patients With Active Relapsing Disease , Merck Press Releases , Merck , Meal , World , Mavenclad , Data , Show , Sustained , Effectiveness , Benefit , Quality , Life , Measures , Patients ,